Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 16, 2024
Daily News
May 16, 2024
- Eisai Begins Rolling Submission for Subcutaneous Leqembi in US
May 16, 2024
- Eisai Sees Global Sales of Leqembi Surging to 56.5 Billion Yen in FY2024
May 16, 2024
- First Innovation Premium in 6 Years Axed for Sargmalin, “Zero” Rule Hits Yet Again
May 16, 2024
- Chuikyo OKs Listing of 18 Meds, All Get Price Premiums; Biggest Peak Sales for Beyfortus
May 16, 2024
- Japan to Increase Reimbursement Rounds to 7 Times a Year from 2025
May 16, 2024
- Alexion Takes Hit from 1st Market Expansion Re-Pricing of Ultomiris, Soliris
May 16, 2024
- Mounjaro Going Back to Normal Supply from June: Lilly/Mitsubishi
May 16, 2024
- Amgen Files BiTE Drug Tarlatamab for Lung Cancer in Japan
May 16, 2024
- BMS’s Sotyktu to Get 8.6% Price Cut in August after Cost-Effectiveness Assessment
May 16, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…